Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Aurora Investment Counsel acquired 26,890 shares of ANI Pharmaceuticals in the second quarter, worth approximately $2.2 million. Institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in EPS versus the $2.04 consensus and $266.04 million in revenue, up 25.8% year over year.
• Analyst sentiment remains positive but cautious: the stock has a “Moderate Buy” consensus rating and a $105.83 target price, while several firms recently lowered targets or downgraded their ratings.

Aurora Investment Counsel bought a new stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The fund bought 26,890 shares of the specialty pharmaceutical company's stock, valued at approximately $2,226,000. Aurora Investment Counsel owned 0.12% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in ANIP. Great Lakes Advisors LLC acquired a new position in shares of ANI Pharmaceuticals in the second quarter worth about $5,089,000. Deutsche Bank AG purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $26,775,000. Rice Hall James & Associates LLC purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $2,364,000. Persistent Asset Partners Ltd purchased a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $76,000. Finally, State of Wyoming acquired a new position in ANI Pharmaceuticals in the 2nd quarter worth about $86,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Up 1.5%

Shares of ANIP opened at $78.02 on Thursday. ANI Pharmaceuticals, Inc. has a 52-week low of $70.15 and a 52-week high of $99.50. The company has a quick ratio of 2.41, a current ratio of 2.91 and a debt-to-equity ratio of 0.99. The stock has a fifty day simple moving average of $80.57 and a two-hundred day simple moving average of $78.94. The company has a market capitalization of $1.79 billion, a PE ratio of 16.81 and a beta of 0.44.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The firm had revenue of $266.04 million for the quarter, compared to analysts' expectations of $260.13 million. During the same quarter in the previous year, the company posted $1.80 EPS. The company's revenue was up 25.8% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

Analysts Set New Price Targets

ANIP has been the topic of a number of recent analyst reports. Canaccord Genuity Group decreased their target price on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating on the stock in a research report on Monday, August 10th. Guggenheim reduced their price objective on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research report on Monday, August 10th. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Finally, Zacks Research lowered shares of ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. Based on data from MarketBeat, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $105.83.

Insider Activity

In other news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the sale, the vice president owned 74,424 shares of the company's stock, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $77.00, for a total transaction of $243,474.00. Following the sale, the senior vice president directly owned 75,534 shares in the company, valued at approximately $5,816,118. The trade was a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 18,987 shares of company stock valued at $1,546,405. Company insiders own 8.10% of the company's stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source